Glucose-dependent insulinotropic polypeptide (GIP).

IF 7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Molecular Metabolism Pub Date : 2025-02-28 DOI:10.1016/j.molmet.2025.102118

Timo D Müller, Alice Adriaenssens, Bo Ahrén, Matthias Blüher, Andreas Birkenfeld, Jonathan E Campbell, Matthew P Coghlan, David D'Alessio, Carolyn F Deacon, Stefano DelPrato, Jonathan D Douros, Daniel J Drucker, Natalie S Figueredo Burgos, Peter R Flatt, Brian Finan, Ruth E Gimeno, Fiona M Gribble, Matthew R Hayes, Christian Hölscher, Jens J Holst, Patrick J Knerr, Filip K Knop, Christine M Kusminski, Arkadiusz Liskiewicz, Guillaume Mabilleau, Stephanie A Mowery, Michael A Nauck, Aaron Novikoff, Frank Reimann, Anna G Roberts, Mette M Rosenkilde, Ricardo J Samms, Philip E Scherer, Randy J Seeley, Kyle W Sloop, Christian Wolfrum, Denise Wootten, Richard D DiMarchi, Matthias H Tschöp

{"title":"Glucose-dependent insulinotropic polypeptide (GIP).","authors":"Timo D Müller, Alice Adriaenssens, Bo Ahrén, Matthias Blüher, Andreas Birkenfeld, Jonathan E Campbell, Matthew P Coghlan, David D'Alessio, Carolyn F Deacon, Stefano DelPrato, Jonathan D Douros, Daniel J Drucker, Natalie S Figueredo Burgos, Peter R Flatt, Brian Finan, Ruth E Gimeno, Fiona M Gribble, Matthew R Hayes, Christian Hölscher, Jens J Holst, Patrick J Knerr, Filip K Knop, Christine M Kusminski, Arkadiusz Liskiewicz, Guillaume Mabilleau, Stephanie A Mowery, Michael A Nauck, Aaron Novikoff, Frank Reimann, Anna G Roberts, Mette M Rosenkilde, Ricardo J Samms, Philip E Scherer, Randy J Seeley, Kyle W Sloop, Christian Wolfrum, Denise Wootten, Richard D DiMarchi, Matthias H Tschöp","doi":"10.1016/j.molmet.2025.102118","DOIUrl":null,"url":null,"abstract":"Background: Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has been overshadowed by the other incretin, glucagon-like peptide 1 (GLP-1), which is the basis for several successful drugs to treat diabetes and obesity. However, there has been a rekindling of interest in GIP biology in recent years, in great part due to pharmacology demonstrating that both GIPR agonism and antagonism may be beneficial in treating obesity and diabetes. This apparent paradox has reinvigorated the field, led to new lines of investigation, and deeper understanding of GIP.Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GIP biology and discuss the therapeutic implications of GIPR signal modification on various diseases.Major conclusions: Following its classification as an incretin hormone, GIP has emerged as a pleiotropic hormone with a variety of metabolic effects outside the endocrine pancreas. The numerous beneficial effects of GIPR signal modification render the peptide an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, drug-induced nausea and both bone and neurodegenerative disorders.","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":" ","pages":"102118"},"PeriodicalIF":7.0000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.molmet.2025.102118","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has been overshadowed by the other incretin, glucagon-like peptide 1 (GLP-1), which is the basis for several successful drugs to treat diabetes and obesity. However, there has been a rekindling of interest in GIP biology in recent years, in great part due to pharmacology demonstrating that both GIPR agonism and antagonism may be beneficial in treating obesity and diabetes. This apparent paradox has reinvigorated the field, led to new lines of investigation, and deeper understanding of GIP.

Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GIP biology and discuss the therapeutic implications of GIPR signal modification on various diseases.

Major conclusions: Following its classification as an incretin hormone, GIP has emerged as a pleiotropic hormone with a variety of metabolic effects outside the endocrine pancreas. The numerous beneficial effects of GIPR signal modification render the peptide an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, drug-induced nausea and both bone and neurodegenerative disorders.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

葡萄糖依赖性促胰岛素多肽（GIP）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Molecular Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

14.50

自引率

2.50%

发文量

219

审稿时长

43 days

期刊介绍： Molecular Metabolism is a leading journal dedicated to sharing groundbreaking discoveries in the field of energy homeostasis and the underlying factors of metabolic disorders. These disorders include obesity, diabetes, cardiovascular disease, and cancer. Our journal focuses on publishing research driven by hypotheses and conducted to the highest standards, aiming to provide a mechanistic understanding of energy homeostasis-related behavior, physiology, and dysfunction. We promote interdisciplinary science, covering a broad range of approaches from molecules to humans throughout the lifespan. Our goal is to contribute to transformative research in metabolism, which has the potential to revolutionize the field. By enabling progress in the prognosis, prevention, and ultimately the cure of metabolic disorders and their long-term complications, our journal seeks to better the future of health and well-being.